Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on March 6, 2026, regarding events occurring on March 5, 2026. The Company is an emerging growth company with its principal executive offices in San Antonio, Texas. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On March 5, 2026, the Board of Directors was informed that two directors, Robert Anderson and Roby Joyce, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for April 30, 2026. Their current terms expire at that meeting. The Company explicitly stated that these departures did not result from any disagreements with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, or specific risks beyond the standard disclosure of the director departures. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the April 30, 2026, Annual Meeting.
- Confirm whether the Company has nominated replacement candidates for the vacancies left by Mr. Anderson and Mr. Joyce.
- Review the Company's most recent 10-K or 10-Q filings for the latest financial metrics, as this 8-K does not contain them.